Core Viewpoint - Henglu Bio has received official approval for its new yeast strain and process for synthesizing Human Milk Oligosaccharides (HMOs) in China, marking a significant step in domestic innovation and production capabilities in the food additives market [2][3]. Group 1: Product Development - Henglu Bio's 2'-Fucosyllactose (2'-FL) has passed the National Health Commission's approval as a new food additive, making it the first company to use a probiotic yeast for HMO production in China [2]. - The production process involves fermentation using glucose and lactose as carbon sources, resulting in high-purity 2'-FL through a series of meticulous steps [2][3]. - The second factory of Henglu Bio is equipped with three 30-cubic-meter fermentation tanks, capable of producing up to 150 tons of 2'-FL annually when operating at full capacity [3]. Group 2: Safety and Quality Assurance - Henglu Bio emphasizes food safety by using Lactococcus lactis as the source organism and Bacillus spp. as the donor, both of which have a strong safety record in the food industry [4][8]. - The yeast strain has a long history of safe application in the food industry, with significant industrial-scale production of lactose enzymes since 1993 [5]. - The use of Bacillus spp. further enhances the safety and controllability of the production process [8]. Group 3: Economic and Environmental Benefits - The production process is economically viable as it utilizes glucose and lactose, with the potential to replace lactose with whey, a byproduct of the dairy industry, thus reducing production costs and addressing whey surplus issues [9]. - The yeast-based production method is environmentally friendly, achieving compliance with "three wastes" standards and enabling flexible production lines for various HMOs, contributing to energy savings and reduced carbon emissions [10].